Introduction

Please take a moment and listen to the introductory video on your left. Then, view the video below and follow the instructions for the quiz.

The video below from the Psychedelic Science in the 21st Century is available for continuing education credit through the co-sponsorhip of the Mulitdisciplinary Association for Psychedelic Studies and the Spiritual Competency Resource Center for many physicians, psychologists, social workers, MFTs, nurses and other healthcare professionals.



INSTRUCTIONS

    1. Watch the video on your left. There is no charge for viewing the video
    2. Answer the questions below.
    3. When finished, press the Score My Quiz button. After that you will have an option to checkout and print your CE/CME certificate.*
    4. To view CE/CME information click here

Clinical Applications of Psychedelics


Course Presenter(s):
Author(s): Alicia Danforth, Ph.D. | Christopher Wiegand, M.D. | (click author name for biography)


Course Description: Results from a study of psilocybin to treat obsessive-compulsive disorder in human subjects. This study investigated the safety, tolerability, and clinical effects of psilocybin, a potent serotonin agonist in nine patients with Obsessive Compulsive Disorder (OCD). Subjects participated in up to 4 single-dose exposures to psilocybin, separated by at least 1 week, in doses ranging from sub-hallucinogenic to frankly hallucinogenic. Sessions lasted 8-hours in a controlled clinical environment, followed by overnight hospitalization. The Yale-Brown Obsessive Compulsive Scale (YBOCS) was administered at specific intervals, and vital signs monitored. One subject experienced transient hypertension without relation to anxiety or so- matic symptoms, but no other significant adverse effects were observed. Marked decreases in OCD symptoms were observed in all subjects during 1 or more of the testing sessions (23%- 100% decrease in YBOCS score) and generally lasted at least 24 hours. In a controlled clinical environment, psilocybin was safely used in subjects with OCD and was associated with acute reductions in core OCD symptoms in several subjects. Psychedelics & MDMA as Potential Supplements to Treament for High- Functioning Autism & Asperger’s Syndrome (CME) A graduate student of clinical psychology and a research associate and co-facilitator for the Harbor-UCLA cancer anxiety trial with psilocybin, Alicia Danforth will provide an overview of the research from the late 1950s through the early 1970s on the use of LSD and psilocybin in the treatment of severe autism in children. She will also discuss the potential use of MDMA-assisted therapy as a supplement to treatment for individuals with high-functioning autism and Asperger’s syndrome. Alicia Danforth, Ph.D candidate
Biography of Presenters:

Alicia Danforth, Ph.D. candidate, is a clinical psychedelic researcher and writer. Since 2006, she has coordinated and co- facilitated treatment sessions for Dr. Charles Grob’s Harbor-UCLA cancer anxiety trial with psilocybin. She also oversees a nationwide web-based recruitment effort for a similar trial currently underway at the Johns Hopkins School of Medicine. Inspired by the results of this work, Alicia began a Ph.D. program in Clinical Psychology at the Institute of Transpersonal Psychology (ITP) in Palo Alto. She was a speaker on the Rising Researchers panel at the World Psychedelic Forum in 2008. She has also given talks and workshops related to her research and the broader psychedelic community at Burning Man, Horizons, Symbiosis, and the Women’s Visionary Council Salon. She also published an original manuscript on using Focusing-oriented psychotherapy techniques as part of preparation for psychedelic therapy sessions in the spring, 2010, edition of the Journal of Transpersonal Psychology.


Christopher Wiegand, M.D., is a psychiatrist currently in private practice in Tucson, Arizona. His clinical practice includes outpatient psychopharmacology and psychotherapy, hospital and nursing home consultation, and electroconvulsive therapy. In addition, Dr. Wiegand is a Clinical Assistant Professor in the Department of Psychiatry at the University of Arizona; he participates in research, resident supervision, and medical student education. He received his B.A. in Archaeology at the University of Virginia in 1995, his M.D. at the University of Virginia in 1999, and completed Psychiatry resi- dency training at the University of Arizona in June, 2003. Dr Wiegand will be discussing the safety, tolerability, and efficacy of psilocybin in patients with Obsessive-Compulsive Disorder (OCD).

Date of original release: April 18, 2010
Termination date (date after which enduring material is no longer certified for credit): April 17, 2012

Alicia Danforth- Psychedelics & MDMA as Potential Supplements to Treat High-Functioning Autism & Asperger’s Syndrome from MAPS: Psychedelic Science on Vimeo.

Chris Wiegand, M.D.,-Results from a study of psilocybin to treat obsessive-compulsive disorder in human subjects from MAPS: Psychedelic Science on Vimeo.

True/False Comprehension Quiz

QuestionAnswer
The research on psychedelics and Aspergers reviewed by Danforth showed no documentable post-session gains in language but there was an increase in eye-to-face contact (sociability) between the participant and the examiner.
Psilocybin is a potent activator at the serotonin 1A, 2A and 2C receptors involved in OCD.
Current OCD treatment with SSRIs (selective serotonin reuptake inhibitors) is only effective in 40 to 60% of OCD patients.
Danforth argues that post-session integration is not helpful when MDMA is to be used as an adjunct to psychotherapy to treat autism.
According to Danforth, many of the challenges associated with Aspergers relate directly to the effects of MDMA. For example where one of the major Aspergers challenges is empathy deficit, MDMA has been shown to increase feelings of empathy.
Danforth argues that psilocybin has the potential to cure autism.
The results Wiegand presents show significant adverse effects/events documented after 29 sessions with psilocybin.
The results equivalent changes in OCD traits following sessions in which participants were given placebos instead of psilocybin.

Rate this Course:
Rating of this course out of 5 votes:44%

 
 


Spiritual Competency Resource Center Website